.png "Alfred Kim, MD, PhD photo")
Washington University School of Medicine
St. Louis, MO, United States
Dr. Kim is an Associate Professor of Medicine at Washington University School of Medicine, where he directs the Lupus Center and the Biobank and Phenotyping Core within the NIH/NIAMS P30-funded Rheumatic Diseases Research Resource-based Center. He is a Faculty Scholar at the Institute of Public Health at Washington University and is the Chief Medical Officer for Kypha, Inc.
Dr. Kim runs a research group that focuses on translational and clinical questions surrounding human systemic lupus erythematosus. Dr. Kim also started the COVID-19 Vaccine Responses in Patients with Autoimmune Diseases (COVaRiPAD) study, which seeks to elucidate the strength, quality, durability, evolution, and safety of COVID-19 vaccine responses in patients who take immunosuppressives for autoimmune diseases.
Dr. Kim chairs the Impact Advisory Council at the RRF, serves as a member of the Scientific Advisory Board at the Lupus Research Alliance, OMERACT SLE Working Group, Lupus Nephritis Trials Network, Lupus Clinical Investigator Network, and Clinical and Scientific Committee of the COVID-19 Global Rheumatology Alliance. He served on the Strategic Planning Task Force for the ACR, RRF Scientific Advisory Council, and Early Career Investigators Subcommittee within the Committee of Research of the ACR.
208: Updated Guidance Calls for the Earlier Use of Biologics: Are You Embracing the Change?
Sunday, November 12, 2023
1:30 PM – 2:15 PM PT
Disclosure(s): ANI Pharmaceuticals: Consultant (Terminated, July 31, 2022); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Consultant (Terminated, April 30, 2022)
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): ANI Pharmaceuticals: Consultant (Terminated, July 31, 2022); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Consultant (Terminated, April 30, 2022)
233: COVID-19 Prevention and Management: Caring for Your Rheumatology Patients
Tuesday, November 14, 2023
6:00 PM – 8:00 PM PT
Disclosure(s): ANI Pharmaceuticals: Consultant (Terminated, July 31, 2022); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Consultant (Terminated, April 30, 2022)
15W122: Genes, Gender, and Gammaglogulins in Severe COVID: Lessons Learned from the Pandemic
Wednesday, November 15, 2023
11:00 AM – 12:00 PM PT
Disclosure(s): ANI Pharmaceuticals: Consultant (Terminated, July 31, 2022); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Consultant (Terminated, April 30, 2022)
